Creative Planning Buys 5,989 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)

Creative Planning boosted its stake in shares of Arbutus Biopharma Co. (NASDAQ:ABUS) by 13.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,500 shares of the biopharmaceutical company’s stock after purchasing an additional 5,989 shares during the quarter. Creative Planning’s holdings in Arbutus Biopharma were worth $191,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in ABUS. nVerses Capital LLC acquired a new stake in Arbutus Biopharma in the second quarter worth about $34,000. Walleye Trading LLC acquired a new stake in Arbutus Biopharma in the first quarter worth about $36,000. Helen Stephens Group LLC acquired a new stake in Arbutus Biopharma in the third quarter worth about $50,000. XTX Topco Ltd acquired a new stake in Arbutus Biopharma in the second quarter worth about $53,000. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Arbutus Biopharma by 22.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 36,388 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 6,649 shares in the last quarter. Institutional investors own 43.79% of the company’s stock.

Arbutus Biopharma Stock Down 0.5 %

NASDAQ:ABUS opened at $3.73 on Tuesday. Arbutus Biopharma Co. has a 52 week low of $1.70 and a 52 week high of $4.72. The company has a market capitalization of $706.80 million, a P/E ratio of -8.91 and a beta of 1.92. The stock’s fifty day moving average is $4.03 and its two-hundred day moving average is $3.59.

Analysts Set New Price Targets

Several research analysts have recently issued reports on ABUS shares. JMP Securities raised their price objective on Arbutus Biopharma to $5.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of Arbutus Biopharma in a research report on Thursday, November 7th. Chardan Capital boosted their price objective on Arbutus Biopharma from $4.00 to $4.50 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Jefferies Financial Group lifted their price target on Arbutus Biopharma from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, September 5th. Finally, StockNews.com raised Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 10th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Arbutus Biopharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.38.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.